HSD11B1
11-beta-hydroxysteroid dehydrogenase 1
As of the edition of 20 October 2026, HSD11B1 (11-beta-hydroxysteroid dehydrogenase 1, UniProt P28845) has 12 drugs tested at it and 10 companies on the list, 9 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28845
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 42
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Mental health; Nervous system; Eye; Blood and lymph; Cancer
- Registered trials of its drugs
- 37
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 6 |
| Stopped | 4 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| BI-187004 | Went quiet | Phase 2 | none listed |
| Emestedastat | Active | Phase 3 | none listed |
| AZD-4017 | Went quiet | Phase 2 | none listed |
| RO5093151 | Went quiet | Phase 2 | none listed |
| Bms-823778 free base | Stopped | Phase 2 | none listed |
| ABT-384 | Went quiet | Phase 2 | none listed |
| AZD8329 | Went quiet | Phase 1 | none listed |
| MK-0736 | Stopped | Phase 2 | none listed |
| MK0916 | Went quiet | Phase 2 | none listed |
| JTT-654 | Stopped | Phase 2 | none listed |
| PF-00915275 | Stopped | Phase 2 | none listed |
| Carbenoxolone | Marketed | No phase stated | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Engaged | 1 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Pfizer | Route A |
| Merck & Co. | Route A |
The other 7 companies at HSD11B1
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at HSD11B1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.